Lv74
4170 积分 2022-10-18 加入
Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Patients With Mild or Moderate Hepatic Impairment Versus Participants With Normal Hepatic Function: A Phase 1 Study
21小时前
已完结
Global prevalence of erectile dysfunction in 2025: a call for updated epidemiological data
1天前
已完结
PDE5抑制剂与cGMP信号通路相关疾病的研究进展
2天前
已完结
Discovery and Optimization of Dihydroquinolin-2(1H)-ones as Novel Highly Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension
2天前
已完结
Pharmacokinetics-Driven Optimization of 4(3H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension
2天前
已完结
PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
2天前
已完结
磷酸二酯酶5抑制剂研发进展
2天前
已完结
西地那非临床研究进展
2天前
已完结
Discovery, Synthesis, and Biological Evaluation of Novel Quinoline-Based PDE4 Inhibitors with Potent Anti-Chronic Obstructive Pulmonary Disease Activity
6天前
已完结
皖公网安备34019202002308
